Shots:

• The 1st patient has been enrolled in a P-III (OPTIC-J) trial to evaluate the efficacy, tolerability & safety of teprotumumab vs PBO in a ratio (1:1) in 50 adults with active TED across the US & EU
• The primary efficacy EPs is proptosis response rate @24wks. & also evaluates ORR, change from baseline in proptosis measurement, diplopia responder rate & change from baseline in the GO-QoL questionnaire @24wks.
• Additionally, patients will enter an OLE period to receive an additional 8 infusions of teprotumumab @24wks. during the 48wk. follow-up, following the completion of the treatment period & proptosis non-responders. The therapy has been marketed under the brand name Tepezza in the US

 Ref: Horizon | Image: Horizon